These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 1932290)

  • 1. Effects of factor VIII concentrates on the immune system in hemophilic patients.
    Schulman S
    Ann Hematol; 1991 Sep; 63(3):145-51. PubMed ID: 1932290
    [No Abstract]   [Full Text] [Related]  

  • 2. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 3. A multicentre prospective cohort study of immune function in patients treated with monoclonally immunopurified or resin-purified SNBTS high-potency factor VIII concentrate.
    Hay CR
    Transfus Sci; 1996 Sep; 17(3):337-8. PubMed ID: 10184610
    [No Abstract]   [Full Text] [Related]  

  • 4. Modulation of allogeneic cytotoxic activity by factor VIII or IX concentrates.
    Soria AG; Bouzas MB; Anselmo A; Ruibal-Ares BH
    Haematologica; 1991; 76(1):33-7. PubMed ID: 1829058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Plasma concentrates of factor VIII. Where are we?].
    Vicente V
    Sangre (Barc); 1989 Feb; 34(1):1-3. PubMed ID: 2496481
    [No Abstract]   [Full Text] [Related]  

  • 6. Antihemophilic factor isolated with monoclonal antibodies.
    Gomperts ED
    Ann Hematol; 1991 Sep; 63(3):142-4. PubMed ID: 1932289
    [No Abstract]   [Full Text] [Related]  

  • 7. A continuing challenge: treatment of hemophilic children with acquired factor VIII inhibitors.
    Bell BA
    Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):105-6. PubMed ID: 8447549
    [No Abstract]   [Full Text] [Related]  

  • 8. [Improvement in anti-hemophilic preparations and its problems. 4. Factor VIII preparation (RCG-5) with intermediate purity and potency].
    Yoshioka A
    Rinsho Ketsueki; 1988 May; 29(5):649-54. PubMed ID: 3145996
    [No Abstract]   [Full Text] [Related]  

  • 9. The case for wider use of recombinant factor VIII concentrates.
    Hermans C; Brackmann HH; Schinco P; Auerswald G
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):11-20. PubMed ID: 21964312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of tolerance using porcine factor VIII.
    Hay CR; Laurian Y
    Vox Sang; 1996; 70 Suppl 1():68-9. PubMed ID: 8869473
    [No Abstract]   [Full Text] [Related]  

  • 11. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological and laboratory aspects of immune tolerance.
    Kazatchkine M; Hoyer L
    Vox Sang; 1996; 70 Suppl 1():52-9. PubMed ID: 8869470
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of factor VIII inhibitors.
    Dimichele DM
    Int J Hematol; 2006 Feb; 83(2):119-25. PubMed ID: 16513529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
    van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
    Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune tolerance in hemophilia and the treatment of hemophiliacs with an inhibitor. Proceedings of a meeting. Palermo, Italy, October 1999.
    Haematologica; 2000 Oct; 85(10 Suppl):1-116. PubMed ID: 11236744
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs.
    Wadhwa M; Dilger P; Tubbs J; Mire-Sluis A; Barrowcliffe T; Thorpe R
    Blood; 1994 Sep; 84(6):2021-30. PubMed ID: 8081003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII inhibitor treatment with high doses of F VIII.
    Stenbjerg S; Ingerslev J; Zachariae E
    Thromb Res; 1984 Jun; 34(6):533-9. PubMed ID: 6429891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIII immunogenicity.
    Jacquemin MG; Saint-Remy JM
    Haemophilia; 1998 Jul; 4(4):552-7. PubMed ID: 9873793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of immune tolerance with factor VIII concentrate in patients with hemophilia A and inhibitors.
    Ewing NP
    Prog Clin Biol Res; 1990; 324():59-68. PubMed ID: 2106693
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibitors in haemophilia A: the role of VWF/FVIII concentrates--a meeting report.
    Kaveri S; Gringeri A; Heisel-Kurth M; Kreuz W
    Haemophilia; 2009 Mar; 15(2):587-91. PubMed ID: 19347997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.